- Home
- TENX vs CLNN Comparison
TENX vs CLNN Comparison
Compare TENX & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- CLNN
- Stock Information
- Founded
- TENX 1967
- CLNN 2012
- Country
- TENX United States
- CLNN United States
- Employees
- TENX N/A
- CLNN N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- CLNN Health Care
- Exchange
- TENX Nasdaq
- CLNN Nasdaq
- Market Cap
- TENX 21.6M
- CLNN 23.1M
- IPO Year
- TENX N/A
- CLNN N/A
- Fundamental
- Price
- TENX $6.17
- CLNN $3.92
- Analyst Decision
- TENX Strong Buy
- CLNN Strong Buy
- Analyst Count
- TENX 3
- CLNN 5
- Target Price
- TENX $16.00
- CLNN $40.00
- AVG Volume (30 Days)
- TENX 35.4K
- CLNN 140.0K
- Earning Date
- TENX 08-12-2025
- CLNN 08-06-2025
- Dividend Yield
- TENX N/A
- CLNN N/A
- EPS Growth
- TENX N/A
- CLNN N/A
- EPS
- TENX N/A
- CLNN N/A
- Revenue
- TENX N/A
- CLNN $350,000.00
- Revenue This Year
- TENX N/A
- CLNN N/A
- Revenue Next Year
- TENX N/A
- CLNN $1,753.57
- P/E Ratio
- TENX N/A
- CLNN N/A
- Revenue Growth
- TENX N/A
- CLNN N/A
- 52 Week Low
- TENX $2.80
- CLNN $2.28
- 52 Week High
- TENX $7.89
- CLNN $7.59
- Technical
- Relative Strength Index (RSI)
- TENX 51.83
- CLNN 52.37
- Support Level
- TENX $5.62
- CLNN $4.12
- Resistance Level
- TENX $6.35
- CLNN $4.40
- Average True Range (ATR)
- TENX 0.46
- CLNN 0.26
- MACD
- TENX 0.01
- CLNN -0.06
- Stochastic Oscillator
- TENX 41.49
- CLNN 7.89
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.